Abstract
A double-blind, placebo-controlled crossover study was undertaken in 10 neuroleptic-treated male schizophrenic outpatients to assess the effect of coadministration of selegiline 15 mg/day for 3 weeks on their sexual dysfunction. Selegiline was not found to be effective in improving any domain of sexual functioning despite a significant decrease in prolactin levels (P < 0.05). This study emphasizes the complex nature of sexual dysfunction in schizophrenic-treated patients and the need for placebo-controlled trials for this condition.
| Original language | English |
|---|---|
| Pages (from-to) | 193-195 |
| Number of pages | 3 |
| Journal | Clinical Neuropharmacology |
| Volume | 26 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jul 2003 |
| Externally published | Yes |
Keywords
- Antipsychotics
- Dopamine
- L-deprenyl
- Neuroleptics
- Schizophrenia
- Selegiline
- Sexual dysfunction
Fingerprint
Dive into the research topics of 'Selegiline in the treatment of sexual dysfunction in schizophrenic patients maintained on neuroleptics: A pilot study'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver